Gerald S Falchook Rom Leidner Elizabeth Stankevich Brian Piening Carlo Bifulco Israel Lowy Matthew G Fury
10.1186/s40425-016-0176-3
J Immunother Cancer
2016 Nov 15;4:70.
basal cell carcinoma cutaneous squamous cell carcinoma immune checkpoint inhibitor mutation burden phase 1 programmed death-1 regn2810
CC BY
https://pubmed.ncbi.nlm.nih.gov/27879972/
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Basal Cell / drug therapy Carcinoma, Squamous Cell / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Skin Neoplasms / drug therapy
Antibodies, Monoclonal / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Carcinoma, Basal Cell / drug therapy Carcinoma, Squamous Cell / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Skin Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Aged Antibodies, Monoclonal / pharmacology Antineoplastic Agents, Immunological / pharmacology Carcinoma, Basal Cell / diagnosis Carcinoma, Basal Cell / metabolism Carcinoma, Squamous Cell / diagnosis Carcinoma, Squamous Cell / metabolism Female Humans Male Middle Aged Neoplasm Metastasis Neoplasm Staging Skin Neoplasms / diagnosis Skin Neoplasms / pathology Tomography, X-Ray Computed Treatment Outcome Antibodies, Monoclonal Antineoplastic Agents, Immunological Programmed Cell Death 1 Receptor
PMC5109769
27879972
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
2016